<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Allogeneic bone marrow transplantation (BMT) is the only curative therapy available for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>In an attempt to identify prognostic factors influencing outcome, we collected data retrospectively on 60 consecutive adult patients who had undergone BMT at our center for primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> evolving from preexisting primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> (sAML) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients were divided into subgroups according to cytogenetic abnormalities based on a recently described International <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> Workshop categorization system </plain></SENT>
<SENT sid="3" pm="."><plain>The 7-year actuarial event-free survival (EFS), relapse rate, and nonrelapse mortality (NRM) for <z:hpo ids='HP_0000001'>all</z:hpo> patients were 29% (95% confidence interval [CI], 16% to 43%), 42% (CI, 24% to 67%), and 50% (CI, 37% to 64%), respectively </plain></SENT>
<SENT sid="4" pm="."><plain>The EFS for the good-, intermediate-, and poor-risk cytogenetic subgroups were 51% (CI, 30% to 69%), 40% (CI, 16% to 63%), and 6% (CI, 0% to 24%), respectively (P = .003) </plain></SENT>
<SENT sid="5" pm="."><plain>The corresponding actuarial relapse rates were 19% (CI, 6% to 49%), 12% (CI, 2% to 61%), and 82% (CI, 48% to 99%), respectively (P =  </plain></SENT>
<SENT sid="6" pm="."><plain>002) with no difference in NRM between the subgroups </plain></SENT>
<SENT sid="7" pm="."><plain>Univariate analysis showed cytogenetic category, French-American-British (FAB) subtype, and <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis used to be predictive of relapse and EFS </plain></SENT>
<SENT sid="8" pm="."><plain>In multivariate analysis, only the cytogenetic category was predictive of EFS, with the relative risk of treatment failure for the good-, intermediate-, and poor-risk cytogenetic subgroups being 1.0, 1.5, and 3.5, respectively (P =  </plain></SENT>
<SENT sid="9" pm="."><plain>004) </plain></SENT>
<SENT sid="10" pm="."><plain>For adults with primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and sAML, even after BMT, poor-risk cytogenetics are predictive of an unfavorable outcome; novel treatment strategies will be required to improve results with allogeneic BMT in this patient population </plain></SENT>
</text></document>